Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAB) with potential usefulness in bispecific mAB generation

Cancer Immunology Immunotherapy

Volumn 44, Issue 5, 1997, Pages 257-264

  Jacobs, Nathalie ^a   Mazzoni, Alessandra ^b   Mezzanzanica, Delia ^b   Negri, Donatella R M ^b   Valota, Olga ^b   Colnaghi, Maria I ^b   Moutschen, Michel P ^a   Boniver, Jacques ^a   Canevari, Silvana ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anti tumor bs mAb Retargeting; Ca2+ flux; CD3 modulation; T cell activation; T cell proliferation

Indexed keywords

BISPECIFIC ANTIBODY; CALCIUM ION; CD3 ANTIGEN; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY BMA 030; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY TR 66; OKT 3; UNCLASSIFIED DRUG;

ACCESSORY CELL; ANTIGEN RECOGNITION; ARTICLE; CALCIUM TRANSPORT; CROSS LINKING; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTIGENS, CD3; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; OVARIAN NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 0030789554     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050381     Document Type: Article

References (42)

1. Blank-Voorthuis CJAC, Braakman E, Ronteltap CPM, Tilly BC, Sturm E, Warnaar SO, Bolhuis RLH (1993) Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3. J Immunol 151:2904
2. Boerman TJG, Massuger OC, Schijf CPT, Claessens RAMJ, Corstens FHM (1996) Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients. Int J Cancer 66:477
3. Bolhuis RLH, Van de Griend RJ (1985) PHA induced proliferation and cytolytic activity in T3+, but not in T3- cloned T lymphocytes, requires the involvement of the T3 antigen for signal transmission. Cell Immunol 93:46
4. Bolhuis RLH, Lamers CHJ, Goey HS, Eggermont AMM, Trimbos JB, Stoter G, Lanzavecchia A, Di Re E, Miotti S, Raspagliesi F, Rivoltini L, Colnaghi MI (1992) Adoptive immunotherapy of ovarian carcinoma with Bs-MAb targeted lymphocytes. A multicenter study. Int J Cancer 7:78
5. Canevari S, Mezzanzanica D, Mazzoni A, Negri DRM, Ramakrishna V, Bolhuis RLH, Colnaghi MI, Bolis G (1995) Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J Hematother 4:423
6. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re E, Eggermont AMM, Goey SH, Gratama JW, Lamers CHJ, Nooy MA, Parmiani G, Raspagliesi F, Ravagnani F, Scarfone G, Trimbos JB, Warnaar SO, Bolhuis RLH (1995) Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87:1463
7. Davis LS, Wacholtz MC, Lipsky PE (1989) The induction of T cell unresponsiveness by rapidly modulating CD3. J Immunol 142:1084
8. De Gast GC, Haagen I-A, Van Houten AA, Klein SC, Duits AJ, De Weger RA, Vroom TM, Clark MR, Phillips J, Van Dijk AJG, De Lau WBM, Bast BJEG (1995) CD8 T cell activation after intravenous administration of CD3 CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 40:390
9. Kroesen BJ, Buter J, Sleijfer DT, Janssen RAJ, Van der Graaf WTA, The TH, de Leij L, Mulder NH (1994) Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer 70:652
10. Lanzavecchia A, Scheidegger D (1987) The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 17:105
11. Ledbetter JA, June CH, Martin PJ, Spooner CE, Hansen JA, Meier KE (1986) Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation. J Immunol 136:3945
12. Marchalonis JJ (1969) An enzymatic method for the trace iodination of immunoglobulin and other proteins. Biochem J 113:299
13. Mezzanzanica D, Canevari S, Ménard S, Pupa SM, Tagliabue E, Lanzavecchia A, Colnaghi MI (1988) Human ovarian carcinoma lysis by cytotoxicity T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J Cancer 41:609
14. 2 antibody prolong host survival in a murine xenograft model. Cancer Res 51:5716
15. Miotti S, Canevari S, Ménard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue E, Colnaghi MI (1987) Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 39:297
16. Mueller DL, Jenkins MK, Schwartz, RH (1989) Clonal expansion vs functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7:445
17. Oettgen HC, Terhorst C, Cantley LC, Rosoff PM (1985) Stimulation of the T3-T cell receptor complex induces a membrane-potential-sensitive calcium influx. Cell 40:583
18. Oi VT, Morrison SL (1986) Chimeric antibodies. Biotechniques 4:214
19. Ortho Multicenter Transplant Study Group (1985) A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337
20. Pichler WJ, Walker C, Bettens F, Koponen M, Von Tscharner V, Kurrle R, Snow C, DeWeck AL (1987) Differences of T cell activation by the anti-CD3 antibodies Leu4 and BMA030. Cell Immunol 108:175
21. 2+]i in individual cytolytic T cells and targets. EMBO J 6:2223
22. Pupa SM, Canevari S, Fontanelli R, Ménard S, Mezzanzanica D, Lanzavecchia A, Colnaghi MI (1988) Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells. Int J Cancer 42:455
23. Pupa SM, Canevari S, Colzani E, Damgard EM, Ménard S, Miotti S, Colnaghi MI (1991) Purification of bispecific monoclonal antibodies produced by a hybrid hybridoma. J Immunol Res 3:16
24. Rabinovitch PS, June CH, Grossmann A, Ledbetter JA (1986) Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. J Immunol 137:952
25. Renner C, Pfreundschuh M (1995) Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev 145:179
26. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, Hartmann F, Diehl V, van Lier R, Pfreundschuh M (1994) Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 264:833
27. Rigley K, Slocombe P, Proudfoot K, Wahid S, Mandair K, Bebbington C (1995) Human p59fyn(T) regulates OKT3-induced calcium influx by a mechanism distinct from PIP2 hydrolysis in Jurkat T cells. J Immunol 154:1136
28. Roosnek E, Lanzavecchia A (1989) Triggering T cells by otherwise inert hybrid anti-CD3/anti-tumor antibodies requires encounter with the specific target cell. J Exp Med 170:297
29. Roosnek EE, Van Lier RA, Aarden LA (1987) Two monoclonal anti-CD3 antibodies can induce different events in human T lymphocyte activation. Eur J Immunol 17:1507
30. Schwinzer R, Franklin RA, Domenico J, Renz H, Gelfand EW (1992) Monoclonal antibodies directed to different epitopes in the CD3-TCR complex induce different states of competence in resting human T cells. J Immunol 148:1322
31. Segal DM, Urch CE, George AJT, Jost CR (1991) Bispecific antibodies in cancer treatment. In: De Vita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer. Lippincott, Philadelphia
32. Spits H, Yssel H, Leeuwenberg J, De Vries JE (1985) Antigen-specific cytotoxic T cell and antigen-specific proliferating T cell clones can be induced to cytolytic activity by monoclonal antibodies against T3. Eur J Immunol 15:88
33. Tibben JG, Boerman OC, Claessens RAMJ, Corstens FHM, Van Deuren M, De Mulder PHM, Van der Meer JWM, Keijser KGG, Massuger LFAG (1993) Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab)2. J Natl Cancer Inst 85:1003
34. Tunnacliffe A, Olsson C, Traunecker A, Krissansen GW, Karjalainen K, De la Hera A (1989) The majority of CD3 epitopes are conferred by the epsilon chain. In: Knapp K, Dörken B, Rieber EP, Stein H, Gilks WR, Schmidt RE, Von dem Borne AEGK (eds) Leucocyte typing, vol IV: White cell differentiation antigens. Oxford University Press, Oxford, p 295
35. Valitutti S, Dessing M, Aktories K (1995) Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J Exp Med 181:577
36. Valitutti S, Müller S, Cella M, Padovan E, Lanzavecchia A (1995) Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148
37. Vandenberghe PA, Ceuppens JL (1990) Flow cytometric measurement of cytoplasmic free calcium in human peripheral blood T lymphocytes with fluo-3, a new fluorescent calcium indicator. J Immunol 127:197
38. Van Wauwe JP, De Mey JR, Goossens JG (1980) OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 124:2708
39. 2+ signal in individual human peripheral T cells. J Immunol 150:5338
40. Weiner GJ, De Gast GC (1995) Bispecific monoclonal antibody therapy of B-cell malignancy. Leuk Lymphoma 16:199
41. Weiss A, Imboden J, Hardy K, Manger B, Terhorst C, Stobo J (1986) The role of the T3/antigen receptor complex in T-cell activation. Annu Rev Immunol 4:593
42. Zhu Z, Carter P (1995) Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. Immunol 155:1903